Clinical Trials Logo

Clinical Trial Summary

Objectives

I. Compare, in a randomized Phase III multi-institutional setting, symptom-free survival time of patients with asymptomatic carcinoma of the prostate (T0-4, N0-2, M0) not suited for local curative treatment who are randomly assigned to immediate vs. delayed endocrine intervention (orchiectomy or luteinizing hormone releasing hormone (LHRH) agonist therapy).

II. Compare the overall survival of these two groups of patients.

III. Compare the time to first evidence of distant progression (N4 or M1) of these two treatment groups.

IV. Evaluate the prognostic significance of pretreatment laboratory data and monitor these parameters following endocrine therapy.

V. Study the prognosis of various sub-groups of patients stratified according to performance status, local tumor extent, nodal status, and choice of endocrine treatment.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01819285
Study type Interventional
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact
Status Completed
Phase Phase 3
Start date February 1990
Completion date September 2010

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03344757 - Health Gatherings - For Your Health After Cancer N/A
Completed NCT03322020 - Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT03149861 - Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR N/A
Not yet recruiting NCT05422911 - Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. Phase 2
Completed NCT01553188 - AMG 386 and Abiraterone for Advanced Prostate Cancer Phase 2